Savara, Inc. (SVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.370.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SVRA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | — | — | 0.3 | 0.0 | — | 0.0 | 0.4 | 0.1 | 0.0 | — | 0.0 | 0.5 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.0 | 0.4 | 0.1 | 0.0 | — | 0.0 | 0.5 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.5 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | — | 9.3 | 11.0 | 9.5 | 8.5 | 7.5 | 7.2 |
| Operating Income | (143.6) | (123.5) | (103.2) | (60.0) | (38.8) | (41.5) | (49.3) | (79.0) | (70.0) | (30.0) | (10.9) | (5.9) | (29.3) | (21.5) | (15.6) | (13.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | 1.2 | 0.5 | 2.6 | — | — | — | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | 0.3 | 2.5 | — | — | — | (0.1) |
| EBT, Incl. Unusual Items | — | (118.8) | (95.9) | (54.7) | (38.2) | (43.0) | (49.6) | (78.2) | (68.6) | (33.4) | (11.3) | — | — | — | — | — |
| Income Tax Expense | — | — | 0.0 | — | — | — | — | (7.1) | (7.1) | (3.6) | (0.4) | 0.0 | 0.0 | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (139.3) | (118.8) | (95.9) | (54.7) | (38.2) | (43.0) | (49.6) | (78.2) | (61.5) | (29.8) | (10.9) | (9.0) | (28.7) | (21.5) | (15.6) | (13.3) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.55) | (0.53) | (0.48) | (0.33) | (0.25) | (0.32) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.55) | (0.53) | (0.48) | (0.33) | (0.25) | (0.32) | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 253.6 | 222.4 | 198.2 | 165.2 | 152.8 | 133.9 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 253.6 | 222.4 | 198.2 | 165.2 | 152.8 | 133.9 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (123.5) | (103.1) | (59.9) | (38.8) | (41.3) | (49.0) | (78.0) | — | — | (10.8) | (5.8) | (29.2) | (21.5) | (15.5) | (13.4) |
| EBIT | (143.6) | (123.5) | (103.2) | (60.0) | (38.8) | (41.5) | (49.3) | (79.0) | (70.0) | (30.0) | (10.9) | (5.9) | (29.3) | (21.5) | (15.6) | (13.4) |
| Effective Tax Rate | — | — | — | — | — | — | — | 9.0% | 10.3% | 10.9% | 3.2% | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.